Abstract: A staining method includes staining a biological sample with a coumarin fluorescent dye to provide a fluorescent-stained sample, and bringing the fluorescent-stained sample into contact with osmium tetroxide, further embedding the sample in an epoxy resin, and subsequently slicing the sample to provide a section sample including the fluorescent-stained sample.

Abstract: The present invention aims to provide a novel glycosyl hesperetin, which is significantly reduced in miscellaneous tastes characteristic of conventional products containing glycosyl hesperetin, and a method for producing the same and uses thereof; and the objects are solved by providing a glycosyl hesperetin which comprises glycosyl hesperetin in an amount of 90% or more by mass but less than 100% by mass, on a dry solid basis, but it does not substantially contain furfural, and a method for producing the same and uses thereof.

Abstract: An object of the present invention is to provide a particulate composition containing crystalline ?,?-trehalose dihydrate, having an advantageous emulsifying ability. The above object is solved by providing a particulate composition comprising crystalline ?,?-trehalose dihydrate, which consists of particles containing ?,?-trehalose and maltose and/or maltotriose, wherein said particulate composition contains ?,?-trehalose in an amount of 70% by weight or higher but 90% by weight or lower, on a dry solid basis; and maltose and/or maltotriose in a total amount of 3% by weight or higher, on a dry solid basis; and has a degree of crystallinity for crystalline ?,?-trehalose dihydrate of 25% or higher but less than 90%, when calculated based on its powder X-ray diffraction profile.

Abstract: The present invention addresses the problem of providing an orally-administrable anti-neurodegenerative disease agent having an action of accelerating neurocyte growth and an action of promoting neurite-outgrowth, and having excellent transfer properties to central nervous tissues. The problem is solved by providing an anti-neurodegenerative disease agent containing a compound represented by General formula 4 as an active ingredient, and having an action of accelerating neurocyte growth, an action of promoting neurite-outgrowth, and an action of scavenging reactive oxygen species. In General formula 4, R10 and R11 represent the same or different alkyl group having 2-8 carbon atoms, and the alkyl group may be either a straight chain or a branched chain. n represents an integer of 0 or 1, and X4? represents a suitable counter anion that is pharmaceutically acceptable.

Abstract: An object of the present invention is to provide a particulate composition containing crystalline ?,?-trehalose dihydrate, having an advantageous emulsifying ability. The above object is solved by providing a particulate composition comprising crystalline ?,?-trehalose dihydrate, which consists of particles containing ?,?-trehalose and maltose and/or maltotriose, wherein said particulate composition contains ?,?-trehalose in an amount of 70% by weight or higher but 90% by weight or lower, on a dry solid basis; and maltose and/or maltotriose in a total amount of 3% by weight or higher, on a dry solid basis; and has a degree of crystallinity for crystalline ?,?-trehalose dihydrate of 25% or higher but less than 90%, when calculated based on its powder X-ray diffraction profile.

Abstract: The present invention aims to provide a novel glycosyl hesperetin, which is significantly reduced in miscellaneous tastes characteristic of conventional products containing glycosyl hesperetin, and a method for producing the same and uses thereof; and the objects are solved by providing a glycosyl hesperetin which comprises glycosyl hesperetin in an amount of 90% or more by mass but less than 100% by mass, on a dry solid basis, but it does not substantially contain furfural, and a method for producing the same and uses thereof.

Abstract: The present invention aims to provide a novel glycosyl hesperetin, which is significantly reduced in miscellaneous tastes characteristic of conventional products containing glycosyl hesperetin, and a method for producing the same and uses thereof; and the objects are solved by providing a glycosyl hesperetin which comprises glycosyl hesperetin in an amount of 90% or more by mass but less than 100% by mass, on a dry solid basis, but it does not substantially contain furfural, and a method for producing the same and uses thereof.

Abstract: [Object] The present invention has an object to provide an external dermal agent for reducing skin yellowness already generated in the skin. [Means to Attain the Object] The above object is solved by providing an external dermal agent for reducing skin yellowness already generated in the skin, which contains hesperetin and/or glycosyl hesperetin as an effective ingredient(s).

Abstract: [Object] The present invention has an object to provide an external dermal agent for reducing skin yellowness already generated in the skin. [Means to Attain the Object] The above object is solved by providing an external dermal agent for reducing skin yellowness already generated in the skin, which contains hesperetin and/or glycosyl hesperetin as an effective ingredient(s).

Abstract: The present invention aims to provide a novel glycosyl hesperetin, which is significantly reduced in miscellaneous tastes characteristic of conventional products containing glycosyl hesperetin, and a method for producing the same and uses thereof; and the objects are solved by providing a glycosyl hesperetin which comprises glycosyl hesperetin in an amount of 90% or more by mass but less than 100% by mass, on a dry solid basis, but it does not substantially contain furfural, and a method for producing the same and uses thereof.

Abstract: The present invention has the first object to provide a monoclonal antibody specific to interferon ? subtype ?8 (IFN?8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFN?8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFN?8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN?8.

Abstract: The present invention has the first object to provide a monoclonal antibody specific to interferon ? subtype ?8 (IFN?8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFN?8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFN?8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN?8.

Abstract: Disclosed are a novel hedgehog protein, i.e., a Desert hedgehog protein of human origin including mature and precursor forms, a DNA encoding the protein, a monoclonal antibody recognizing the protein, a process for producing the protein, and a method for detecting the protein. The hedgehog protein is useful in establishment of hybridomas which produce antibodies recognizing the protein, and the monoclonal antibody is useful in detection and purification of the protein. The hedgehog protein, DNA, and monoclonal antibody of this invention have efficacy in elucidation of hereditary morphological abnormalities in humans to establish their treatments and diagnoses.

Abstract: Disclosed are a novel hedgehog protein, i.e., a Desert hedgehog protein of human origin including mature and precursor forms, a DNA encoding the protein, a monoclonal antibody recognizing the protein, a process for producing the protein, and a method for detecting the protein. The hedgehog protein is useful in establishment of hybridomas which produce antibodies recognizing the protein, and the monoclonal antibody is useful in detection and purification of the protein. The hedgehog protein, DNA, and monoclonal antibody of this invention have efficacy in elucidation of hereditary morphological abnormalities in humans to establish their treatments and diagnoses.

Abstract: A process for producing a polyether polymer by polymerizing a monomer having an oxirane group in the presence of a Lewis base having no active hydrogen such as, for example, a nitrile compound, a cyclic ether compound or an ester compound; and a polyether polymer produced by this process. Thus, a polyether polymer having a minimized amount of undesirable crosslinked product can be produced without reduction of polymerization activity.

Abstract: Disclosed are a mammalian trehalose receptor which comprises a protein comprising any of the amino acid sequences of SEQ ID NOs: 1, 2, 3 and 5; or a protein comprising any of the amino acid sequences of SEQ ID NOs: 1, 4 and 5; and a method for detecting trehalose using an animal cell in which the trehalose receptor has been expressed.

Abstract: Disclosed are a novel hedgehog protein, i.e., a Desert hedgehog protein of human origin including mature and precursor forms, a DNA encoding the protein, a monoclonal antibody recognizing the protein, a process for producing the protein, and a method for detecting the protein. The hedgehog protein is useful in establishment of hybridomas which produce antibodies recognizing the protein, and the monoclonal antibody is useful in detection and purification of the protein. The hedgehog protein, DNA, and monoclonal antibody of this invention have efficacy in elucidation of hereditary morphological abnormalities in humans to establish their treatments and diagnoses.